DOI:
10.1055/s-00035024
Thrombosis and Haemostasis
LinksClose Window
References
Yoneyama K, Schmitt C, Kotani N. et al.
A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A.
Clin Pharmacokinet 2018;
57 (09) 1123-1134
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.